{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T19:12:24Z","timestamp":1790104344111,"version":"4.0.1"},"reference-count":80,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,4,9]],"date-time":"2023-04-09T00:00:00Z","timestamp":1680998400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004195","name":"Ocean University of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004195","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007129","name":"Natural Science Foundation of Shandong Province","doi-asserted-by":"publisher","award":["ZR2019BC025"],"award-info":[{"award-number":["ZR2019BC025"]}],"id":[{"id":"10.13039\/501100007129","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.1016\/j.ejps.2023.106443","type":"journal-article","created":{"date-parts":[[2023,4,10]],"date-time":"2023-04-10T11:25:53Z","timestamp":1681125953000},"page":"106443","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["Physiologically-based pharmacokinetic modeling to inform dosing regimens and routes of administration of rifampicin and colistin combination against Acinetobacter baumannii"],"prefix":"10.1016","volume":"185","author":[{"given":"Jiayuan","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chu","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengyuan","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiali","family":"Yue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shixing","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peijuan","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles","family":"OO","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan-Frederik","family":"Schlender","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhihua","family":"LV","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanqi","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sherwin K.B.","family":"SY","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingming","family":"YU","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejps.2023.106443_bib0001","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1016\/j.jsps.2020.06.023","article-title":"Inhaled colistin for the treatment of nosocomial pneumonia due to multidrug-resistant Gram-negative bacteria: a real-life experience in tertiary care hospitals in Saudi Arabia","volume":"28","author":"Almangour","year":"2020","journal-title":"Saudi Pharm. J."},{"key":"10.1016\/j.ejps.2023.106443_bib0002","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1111\/2049-632X.12125","article-title":"Acinetobacter baumannii: evolution of a global pathogen","volume":"71","author":"Antunes","year":"2014","journal-title":"Pathog. Dis."},{"key":"10.1016\/j.ejps.2023.106443_bib0003","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1093\/jac\/dkn530","article-title":"Efficacy of colistin combination therapy in a mouse model of pneumonia caused by multidrug-resistant Pseudomonas aeruginosa","volume":"63","author":"Aoki","year":"2009","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.ejps.2023.106443_bib0004","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1128\/AAC.21.5.800","article-title":"Rifampin blood and tissue levels in patients undergoing cardiac valve surgery","volume":"21","author":"Archer","year":"1982","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejps.2023.106443_bib0005","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1017\/S095026881200194X","article-title":"Colistin vs. the combination of colistin and rifampicin for the treatment of carbapenem-resistant Acinetobacter baumannii ventilator-associated pneumonia","volume":"141","author":"Aydemir","year":"2013","journal-title":"Epidemiol. Infect."},{"key":"10.1016\/j.ejps.2023.106443_bib0006","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/1476-0711-12-15","article-title":"Hetero- and adaptive resistance to polymyxin B in OXA-23-producing carbapenem-resistant Acinetobacter baumannii isolates","volume":"12","author":"Barin","year":"2013","journal-title":"Ann. Clin. Microbiol. Antimicrob."},{"key":"10.1016\/j.ejps.2023.106443_bib0007","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1002\/ajh.2830120414","article-title":"Mixed myeloid-Lymphoid colonies in a patient with polycythemia vera","volume":"12","author":"Beckman","year":"1982","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.ejps.2023.106443_bib0008","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1111\/bcp.13872","article-title":"Physiologically-based pharmacokinetics of ziprasidone in pregnant women","volume":"85","author":"Biesdorf","year":"2019","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.ejps.2023.106443_bib0009","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1111\/j.1365-3164.2009.00856.x","article-title":"New concepts in antimicrobial susceptibility testing: the mutant prevention concentration and mutant selection window approach","volume":"20","author":"Blondeau","year":"2009","journal-title":"Vet. Dermatol."},{"key":"10.1016\/j.ejps.2023.106443_bib0010","doi-asserted-by":"crossref","first-page":"7331","DOI":"10.1128\/AAC.03510-14","article-title":"Comparison of intrapulmonary and systemic pharmacokinetics of colistin methanesulfonate (CMS) and colistin after aerosol delivery and intravenous administration of CMS in critically ill patients","volume":"58","author":"Boisson","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejps.2023.106443_bib0011","series-title":"Antibiotic resistance threats in the United States","year":"2019"},{"key":"10.1016\/j.ejps.2023.106443_bib0012","first-page":"3291","article-title":"New pharmacokinetic\/pharmacodynamic studies of systemically administered colistin against Pseudomonas aeruginosa and Acinetobacter baumannii in mouse thigh and lung infection models: smaller response in lung infection","volume":"70","author":"Cheah","year":"2015","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.ejps.2023.106443_bib0013","series-title":"Performance Standards for Antimicrobial Susceptibility Testing","year":"2020"},{"key":"10.1016\/j.ejps.2023.106443_bib0014","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1023\/B:PHAM.0000026434.82855.69","article-title":"Predicting P-glycoprotein effects on oral absorption: correlation of transport in Caco-2 with drug pharmacokinetics in wild-type and mdr1a(-\/-) mice in vivo","volume":"21","author":"Collett","year":"2004","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejps.2023.106443_bib0015","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1128\/AAC.44.4.985-990.2000","article-title":"Single-dose intrapulmonary pharmacokinetics of rifapentine in normal subjects","volume":"44","author":"Conte","year":"2000","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejps.2023.106443_bib0016","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1111\/j.1469-0691.2011.03667.x","article-title":"Colistin pharmacokinetics: the fog is lifting","volume":"18","author":"Couet","year":"2012","journal-title":"Clin. Microbiol. Infect."},{"key":"10.1016\/j.ejps.2023.106443_bib0017","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1097\/FTD.0000000000000172","article-title":"Colistin: revival of an old polymyxin antibiotic","volume":"37","author":"Dijkmans","year":"2015","journal-title":"Ther. Drug Monit."},{"key":"10.1016\/j.ejps.2023.106443_bib0018","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1038\/nrmicro1789","article-title":"An increasing threat in hospitals: multidrug-resistant Acinetobacter baumannii","volume":"5","author":"Dijkshoorn","year":"2007","journal-title":"Nat. Rev. Microbiol."},{"key":"10.1016\/j.ejps.2023.106443_bib0019","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1093\/cid\/cit253","article-title":"Colistin and rifampicin compared with colistin alone for the treatment of serious infections due to extensively drug-resistant Acinetobacter baumannii: a multicenter, randomized clinical trial","volume":"57","author":"Durante-Mangoni","year":"2013","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.ejps.2023.106443_bib0020","doi-asserted-by":"crossref","first-page":"11339","DOI":"10.1038\/s41598-021-90709-2","article-title":"Pharmacodynamic evaluation of suppression of in vitro resistance in Acinetobacter baumannii strains using polymyxin B-based combination therapy","volume":"11","author":"Fedrigo","year":"2021","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ejps.2023.106443_bib0021","doi-asserted-by":"crossref","first-page":"2875","DOI":"10.1093\/jac\/dkab292","article-title":"Aztreonam\/avibactam effect on pharmacodynamic indices for mutant selection of Escherichia coli and Klebsiella pneumoniae harbouring serine- and New Delhi metallo-beta-lactamases","volume":"76","author":"Feng","year":"2021","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.ejps.2023.106443_bib0022","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1007\/BF01682159","article-title":"Acinetobacter species as nosocomial pathogens","volume":"17","author":"Forster","year":"1998","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"10.1016\/j.ejps.2023.106443_bib0023","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S0732-8893(01)00258-9","article-title":"Interactions of colistin and rifampin on multidrug-resistant Acinetobacter baumannii","volume":"40","author":"Giamarellos-Bourboulis","year":"2001","journal-title":"Diagn. Microbiol. Infect. Dis."},{"key":"10.1016\/j.ejps.2023.106443_bib0024","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1128\/AAC.01624-13","article-title":"In vitro pharmacodynamics of polymyxin B and tigecycline alone and in combination against carbapenem-resistant Acinetobacter baumannii","volume":"58","author":"Hagihara","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejps.2023.106443_bib0025","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1021\/acschembio.7b00836","article-title":"Polymyxin-induced lipid A deacylation in pseudomonas aeruginosa perturbs polymyxin penetration and confers high-level resistance","volume":"13","author":"Han","year":"2018","journal-title":"ACS Chem. Biol."},{"key":"10.1016\/j.ejps.2023.106443_bib0026","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1002\/psp4.12343","article-title":"PBPK models for CYP3A4 and P-gp DDI prediction: a modeling network of rifampicin, itraconazole, clarithromycin, midazolam, alfentanil, and digoxin","volume":"7","author":"Hanke","year":"2018","journal-title":"CPT Pharmacomet. Syst. Pharmacol."},{"key":"10.1016\/j.ejps.2023.106443_bib0027","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1159\/000363495","article-title":"Continuous renal replacement therapy-related strategies to avoid colistin toxicity: a clinically orientated review","volume":"37","author":"Honore","year":"2014","journal-title":"Blood Purif."},{"key":"10.1016\/j.ejps.2023.106443_bib0028","doi-asserted-by":"crossref","first-page":"5925","DOI":"10.1128\/AAC.00808-15","article-title":"Mucin binding reduces colistin antimicrobial activity","volume":"59","author":"Huang","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejps.2023.106443_bib0029","doi-asserted-by":"crossref","first-page":"e63","DOI":"10.1038\/psp.2013.41","article-title":"Basic concepts in physiologically based pharmacokinetic modeling in drug discovery and development","volume":"2","author":"Jones","year":"2013","journal-title":"CPT Pharmacomet. Syst. Pharmacol."},{"key":"10.1016\/j.ejps.2023.106443_bib0030","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1016\/S1473-3099(08)70279-2","article-title":"Current control and treatment of multidrug-resistant Acinetobacter baumannii infections","volume":"8","author":"Karageorgopoulos","year":"2008","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.ejps.2023.106443_bib0031","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.ijpharm.2018.07.011","article-title":"Considerations in preparing for clinical studies of inhaled rifampicin to enhance tuberculosis treatment","volume":"548","author":"Khadka","year":"2018","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejps.2023.106443_bib0032","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejpb.2021.02.011","article-title":"Pharmacokinetics of rifampicin after repeated intra-tracheal administration of amorphous and crystalline powder formulations to Sprague Dawley rats","volume":"162","author":"Khadka","year":"2021","journal-title":"Eur. J. Pharm. Biopharma"},{"key":"10.1016\/j.ejps.2023.106443_bib0033","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2021.120345","article-title":"Studies on the safety and the tissue distribution of inhaled high-dose amorphous and crystalline rifampicin in a rat model","volume":"597","author":"Khadka","year":"2021","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejps.2023.106443_bib0034","doi-asserted-by":"crossref","first-page":"3738","DOI":"10.1128\/AAC.00703-13","article-title":"Synergistic activity of colistin and rifampin combination against multidrug-resistant Acinetobacter baumannii in an in vitro pharmacokinetic\/pharmacodynamic model","volume":"57","author":"Lee","year":"2013","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejps.2023.106443_bib0035","first-page":"134","article-title":"Rifampin breakpoint for Acinetobacter baumannii based on pharmacokinetic-pharmacodynamic models with Monte Carlo simulation","volume":"25","author":"Lepe","year":"2012","journal-title":"Rev. Esp. Quimioter."},{"key":"10.1016\/j.ejps.2023.106443_bib0036","doi-asserted-by":"crossref","first-page":"2857","DOI":"10.1128\/AAC.00030-09","article-title":"Renal disposition of colistin in the isolated perfused rat kidney","volume":"53","author":"Ma","year":"2009","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejps.2023.106443_bib0037","doi-asserted-by":"crossref","first-page":"291","DOI":"10.4103\/0974-777X.68538","article-title":"Multidrug resistant acinetobacter","volume":"2","author":"Manchanda","year":"2010","journal-title":"J. Glob. Infect. Dis."},{"key":"10.1016\/j.ejps.2023.106443_bib0038","doi-asserted-by":"crossref","first-page":"4907","DOI":"10.1128\/AAC.00345-09","article-title":"Penetration of colistin into cerebrospinal fluid","volume":"53","author":"Markantonis","year":"2009","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejps.2023.106443_bib0039","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1111\/bcp.14456","article-title":"Physiologically based pharmacokinetic-pharmacodynamic evaluation of meropenem plus fosfomycin in paediatrics","volume":"87","author":"Martins","year":"2021","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.ejps.2023.106443_bib0040","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1111\/j.1574-6976.2012.00344.x","article-title":"Acinetobacter baumannii: human infections, factors contributing to pathogenesis and animal models","volume":"37","author":"McConnell","year":"2013","journal-title":"FEMS Microbiol. Rev."},{"key":"10.1016\/j.ejps.2023.106443_bib0041","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1128\/AAC.47.3.863-868.2003","article-title":"Low-level resistance to rifampin in Streptococcus pneumoniae","volume":"47","author":"Meier","year":"2003","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejps.2023.106443_bib0042","doi-asserted-by":"crossref","first-page":"63","DOI":"10.2174\/1874285801711010063","article-title":"Synergistic effect of colistin and rifampin against multidrug resistant acinetobacter baumannii: a systematic review and meta-analysis","volume":"11","author":"Mohammadi","year":"2017","journal-title":"Open Microbiol. J."},{"key":"10.1016\/j.ejps.2023.106443_bib0043","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.jinf.2005.11.019","article-title":"Colistin and rifampicin in the treatment of nosocomial infections from multiresistant Acinetobacter baumannii","volume":"53","author":"Motaouakkil","year":"2006","journal-title":"J. Infect."},{"key":"10.1016\/j.ejps.2023.106443_bib0044","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1016\/j.bcp.2011.08.003","article-title":"Human arylacetamide deacetylase is responsible for deacetylation of rifamycins: rifampicin, rifabutin, and rifapentine","volume":"82","author":"Nakajima","year":"2011","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.ejps.2023.106443_bib0045","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1093\/cid\/ciw839","article-title":"Dosing guidance for intravenous colistin in critically-ill patients","volume":"64","author":"Nation","year":"2017","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.ejps.2023.106443_bib0046","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1093\/jac\/29.6.719","article-title":"Penetration of rifampicin into the cerebrospinal fluid of adults with uninflamed meninges","volume":"29","author":"Nau","year":"1992","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.ejps.2023.106443_bib0047","doi-asserted-by":"crossref","first-page":"643","DOI":"10.3389\/fmicb.2014.00643","article-title":"Mechanisms of polymyxin resistance: acquired and intrinsic resistance in bacteria","volume":"5","author":"Olaitan","year":"2014","journal-title":"Front Microbiol."},{"key":"10.1016\/j.ejps.2023.106443_bib0048","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1128\/CMR.00058-07","article-title":"Acinetobacter baumannii: emergence of a successful pathogen","volume":"21","author":"Peleg","year":"2008","journal-title":"Clin. Microbiol. Rev."},{"key":"10.1016\/j.ejps.2023.106443_bib0049","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1128\/AAC.04808-14","article-title":"Molecular mechanisms of sulbactam antibacterial activity and resistance determinants in Acinetobacter baumannii","volume":"59","author":"Penwell","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejps.2023.106443_bib0050","doi-asserted-by":"crossref","first-page":"578","DOI":"10.3390\/pharmaceutics11110578","article-title":"Development and evaluation of physiologically based pharmacokinetic drug-disease models for predicting rifampicin exposure in tuberculosis and cirrhosis populations","volume":"11","author":"Rasool","year":"2019","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ejps.2023.106443_bib0051","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1002\/cpt.2198","article-title":"Model-informed drug development for anti-infectives: state of the art and future","volume":"109","author":"Rayner","year":"2021","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.ejps.2023.106443_bib0052","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1007\/s00134-005-2691-4","article-title":"Safety and efficacy of colistin in Acinetobacter and Pseudomonas infections: a prospective cohort study","volume":"31","author":"Reina","year":"2005","journal-title":"Intensive Care Med."},{"key":"10.1016\/j.ejps.2023.106443_bib0053","doi-asserted-by":"crossref","first-page":"637","DOI":"10.2165\/11594090-000000000-00000","article-title":"Penetration of anti-infective agents into pulmonary epithelial lining fluid: focus on antibacterial agents","volume":"50","author":"Rodvold","year":"2011","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.ejps.2023.106443_bib0054","doi-asserted-by":"crossref","first-page":"e523","DOI":"10.1093\/cid\/ciaa121","article-title":"Clinical and laboratory standards institute and european committee on antimicrobial susceptibility testing position statements on polymyxin B and colistin clinical breakpoints","volume":"71","author":"Satlin","year":"2020","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.ejps.2023.106443_bib0055","doi-asserted-by":"crossref","first-page":"167","DOI":"10.3109\/07853890109002073","article-title":"Multidrug-resistant bacteria: overcoming antibiotic permeability barriers of gram-negative bacteria","volume":"33","author":"Savage","year":"2001","journal-title":"Ann. Med."},{"key":"10.1016\/j.ejps.2023.106443_bib0056","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.tiv.2007.09.010","article-title":"General approach for the calculation of tissue to plasma partition coefficients","volume":"22","author":"Schmitt","year":"2008","journal-title":"Toxicol. In Vitro"},{"key":"10.1016\/j.ejps.2023.106443_bib0057","doi-asserted-by":"crossref","first-page":"5191","DOI":"10.1021\/acs.biochem.6b00461","article-title":"Insight into the mechanism of hydrolysis of meropenem by OXA-23 serine-beta-lactamase gained by quantum mechanics\/molecular mechanics calculations","volume":"55","author":"Sgrignani","year":"2016","journal-title":"Biochemistry"},{"key":"10.1016\/j.ejps.2023.106443_bib0058","doi-asserted-by":"crossref","first-page":"200","DOI":"10.14336\/AD.2020.0103","article-title":"The interstitial system of the brain in health and disease","volume":"11","author":"Shetty","year":"2020","journal-title":"Aging Dis."},{"key":"10.1016\/j.ejps.2023.106443_bib0059","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1093\/jac\/dkm136","article-title":"In vitro activities of carbapenem\/sulbactam combination, colistin, colistin\/rifampicin combination and tigecycline against carbapenem-resistant Acinetobacter baumannii","volume":"60","author":"Song","year":"2007","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.ejps.2023.106443_bib0060","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1007\/s11908-017-0596-3","article-title":"Polymyxin resistance in gram-negative pathogens","volume":"19","author":"Srinivas","year":"2017","journal-title":"Curr. Infect. Dis. Rep."},{"key":"10.1016\/j.ejps.2023.106443_bib0061","doi-asserted-by":"crossref","DOI":"10.1128\/mSphere.00895-19","article-title":"New mutations involved in colistin resistance in Acinetobacter baumannii","volume":"5","author":"Sun","year":"2020","journal-title":"mSphere"},{"key":"10.1016\/j.ejps.2023.106443_bib0062","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1128\/AAC.01717-13","article-title":"Estimation of intracellular concentration of stavudine triphosphate in HIV-infected children given a reduced dose of 0.5 milligrams per kilogram twice daily","volume":"58","author":"Sy","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejps.2023.106443_bib0063","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.ijantimicag.2014.12.016","article-title":"Effect of reducing the paediatric stavudine dose by half: a physiologically-based pharmacokinetic model","volume":"45","author":"Sy","year":"2015","journal-title":"Int. J. Antimicrob. Agents"},{"key":"10.1016\/j.ejps.2023.106443_bib0064","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/978-1-4939-1304-6_1","article-title":"Introduction to pharmacometrics and quantitative pharmacology with an emphasis on physiologically based pharmacokinetics","volume":"14","author":"Sy","year":"2014","journal-title":"Appl. Pharmacomet."},{"key":"10.1016\/j.ejps.2023.106443_bib0065","doi-asserted-by":"crossref","first-page":"338","DOI":"10.3390\/antibiotics10030338","article-title":"Cystic fibrosis: recent insights into inhaled antibiotic treatment and future perspectives","volume":"10","author":"Taccetti","year":"2021","journal-title":"Antibiotics (Basel)"},{"key":"10.1016\/j.ejps.2023.106443_bib0066","doi-asserted-by":"crossref","first-page":"3987","DOI":"10.1128\/AAC.01468-07","article-title":"Pharmacodynamic modeling of aminoglycosides against Pseudomonas aeruginosa and Acinetobacter baumannii: identifying dosing regimens to suppress resistance development","volume":"52","author":"Tam","year":"2008","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejps.2023.106443_bib0067","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1093\/jac\/42.2.270","article-title":"Evaluation of the activities of two-drug combinations of rifampicin, polymyxin B and ampicillin\/sulbactam against Acinetobacter baumannii","volume":"42","author":"Tascini","year":"1998","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.ejps.2023.106443_bib0068","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1124\/jpet.102.043026","article-title":"Human organic anion transporting polypeptide-C (SLC21A6) is a major determinant of rifampin-mediated pregnane X receptor activation","volume":"304","author":"Tirona","year":"2003","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.ejps.2023.106443_bib0069","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1016\/j.ijantimicag.2016.09.010","article-title":"Pharmacokinetics\/pharmacodynamics of colistin and polymyxin B: are we there yet?","volume":"48","author":"Tran","year":"2016","journal-title":"Int. J. Antimicrob. Agents"},{"key":"10.1016\/j.ejps.2023.106443_bib0070","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1002\/phar.2209","volume":"39","author":"Tsuji","year":"2019","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.ejps.2023.106443_bib0071","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ijantimicag.2017.05.016","article-title":"Inhaled colistin monotherapy for respiratory tract infections in adults without cystic fibrosis: a systematic review and meta-analysis","volume":"51","author":"Vardakas","year":"2018","journal-title":"Int. J. Antimicrob. Agents"},{"key":"10.1016\/j.ejps.2023.106443_bib0072","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1007\/s40265-014-0267-8","article-title":"Treatment options for carbapenem-resistant and extensively drug-resistant Acinetobacter baumannii infections","volume":"74","author":"Viehman","year":"2014","journal-title":"Drugs"},{"issue":"Suppl 3","key":"10.1016\/j.ejps.2023.106443_bib0073","doi-asserted-by":"crossref","first-page":"S407","DOI":"10.1093\/clinids\/5.Supplement_3.S407","article-title":"Rifampin: mechanisms of action and resistance","volume":"5","author":"Wehrli","year":"1983","journal-title":"Rev. Infect. Dis."},{"key":"10.1016\/j.ejps.2023.106443_bib0074","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1128\/CMR.00058-16","article-title":"Clinical and pathophysiological overview of acinetobacter infections: a century of challenges","volume":"30","author":"Wong","year":"2017","journal-title":"Clin. Microbiol. Rev."},{"key":"10.1016\/j.ejps.2023.106443_bib0075","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01676-18","article-title":"OXA-23 is a prevalent mechanism contributing to sulbactam resistance in diverse acinetobacter baumannii clinical strains","volume":"63","author":"Yang","year":"2019","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejps.2023.106443_bib0076","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.jinf.2008.11.002","article-title":"Colistin hetero-resistance in multidrug-resistant Acinetobacter baumannii clinical isolates from the Western Pacific region in the SENTRY antimicrobial surveillance programme","volume":"58","author":"Yau","year":"2009","journal-title":"J. Infect."},{"key":"10.1016\/j.ejps.2023.106443_bib0077","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1128\/AAC.48.3.753-757.2004","article-title":"In vitro double and triple synergistic activities of Polymyxin B, imipenem, and rifampin against multidrug-resistant Acinetobacter baumannii","volume":"48","author":"Yoon","year":"2004","journal-title":"Antimicrob. Agents Chemother."},{"issue":"1","key":"10.1016\/j.ejps.2023.106443_bib0078","doi-asserted-by":"crossref","first-page":"251","DOI":"10.3390\/pharmaceutics15010251","article-title":"Pharmacokinetic\/pharmacodynamic evaluation of aztreonam\/amoxicillin\/clavulanate combination against New Delhi metallo-beta-lactamase and serine-beta-lactamase co-producing Escherichia coli and Klebsiella pneumoniae","volume":"15","author":"Zhang","year":"2023","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ejps.2023.106443_bib0079","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1007\/s40262-022-01161-y","article-title":"Prediction of tissue exposures of meropenem, colistin, and sulbactam in pediatrics using physiologically based pharmacokinetic modeling","volume":"61","author":"Zhu","year":"2022","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.ejps.2023.106443_bib0080","doi-asserted-by":"crossref","DOI":"10.3389\/fmicb.2022.1013939","article-title":"Metabolomic profiling of polymyxin-B in combination with meropenem and sulbactam against multi-drug resistant Acinetobacter baumannii","volume":"13","author":"Zhu","year":"2022","journal-title":"Front. Microbiol."}],"container-title":["European Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S092809872300074X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S092809872300074X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T12:06:11Z","timestamp":1760529971000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S092809872300074X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6]]},"references-count":80,"alternative-id":["S092809872300074X"],"URL":"https:\/\/doi.org\/10.1016\/j.ejps.2023.106443","relation":{},"ISSN":["0928-0987"],"issn-type":[{"value":"0928-0987","type":"print"}],"subject":[],"published":{"date-parts":[[2023,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Physiologically-based pharmacokinetic modeling to inform dosing regimens and routes of administration of rifampicin and colistin combination against Acinetobacter baumannii","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmaceutical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejps.2023.106443","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"106443"}}